In the phase 3 DESTINY-Lung04 trial, patients with HER2-mutant advanced non-small cell lung cancer treated with Enhertu went ...

A reflection on shame, vulnerability and transformation, and how driftwood, the ocean and presence helped reshape one man's ...

Patients with early-stage EGFR-mutated non-small cell lung cancer (NSCLC) who took Tagrisso (osimertinib) for three years ...

In this installment of Clinical Trial Corner, Dr. Dina Khalaf, a clinical associate professor in the University of Florida ...

WCLC 2026 brought new lung cancer data on HER2-mutant, PD-L1-positive and EGFR exon 20 insertion-positive non-small cell lung ...

A dedicated movement space can serve as a survivorship anchor, reinforcing identity, agency, and continuity through training ...

A peritoneal mesothelioma diagnosis at 21, five months postpartum, underscores the psychosocial burden of rare malignancy in ...

The FDA granted final approval to OMCAZIO, a new cabozantinib capsule formulation for certain patients with kidney, liver and ...

Now, survivorship means that I have been through an experience that has forever shaped who I am, how I respond and what I ...

Biomarker-matched agents increasingly supplant empiric chemo, with approvals typically starting in refractory metastatic ...

Lymphoma comprises more than 70 non-Hodgkin subtypes; precise classification determines prognosis and drives distinct strategies for aggressive versus indolent disease biology. Management of indolent ...

Patients should never view the first denial as the final answer. Whether it's Medicare, Medicaid, an employer-sponsored plan ...